CRISPR May Prove Useful in De-Extinction Efforts

Researchers are using the powerful gene-editing tool to recreate the woolly mammoth.

Written byBritt Wray
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

GREYSTONE BOOKS, OCTOBER 2017There may come a day when woolly mammoth–like proxies with imposing curled tusks and that iconic, shaggy mane will traipse again through their ancestral stomping grounds in the Siberian tundra. The woolly mammoth went extinct after the last holdouts on Wrangle Island, off the northern coast of far eastern Siberia, died off between 3,600 and 4,000 years ago. For now, however, the promise of this futuristic vision lives in labs at Harvard Medical School—and the cells in petri dishes are a long way off from assembling into a complete animal. Researchers are nowhere close to recreating fully formed mammoths, and, thus far, scientific efforts to resurrect the extinct beasts have been rather incremental. But that hasn’t kept Harvard Medical School researcher George Church from predicting that he and his colleagues, who collaborate on a de-extinction project known as the Woolly Mammoth Revival, will create a hybrid woolly mammoth-Asian elephant embryo as early as 2019. And CRISPR-Cas9, a gene-editing technology that Church’s lab played a role in developing, may be the key to speeding the eventual return of the ancient animal.

I explore this and other tales of de-extinction in my book, Rise of the Necrofauna.

Bobby Dhadwar, a postdoctoral researcher in Church’s lab, has been laying some of the groundwork for creating the engineered embryos. Since the project’s early days, he has been involved in editing “background cell types” in order to test the effects certain woolly mammoth–specific genetic changes have on available cells that most resemble those of a mammoth: Asian elephant cells.

To start, Dhadwar and his colleagues identified traits that people normally attribute to the woolly mammoth, but that are missing in Asian elephants. These include an abundance of reddish-brown hair and a form of oxygen- binding hemoglobin that functions well at low temperatures. In their early experiments, the researchers went hunting ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

September 2017

Healing with Hallucinogens

The therapeutic benefits of psychedelic drugs

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies